Search Team

Search by Last Name
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Speaking Engagement

Pharma Intelligence Webinar | Designing the Deal: Layering the Groundwork for Successful Investment, Partnerships, and Acquisition

Tuesday, June 29th, 2021

Speaking Engagement

Pharma Intelligence Webinar | Designing the Deal: Layering the Groundwork for Successful Investment, Partnerships, and Acquisition

Tuesday, June 29th, 2021, 1:00 pm EDT

​Fish Principal Chad Shear will be a panelist on Informa’s Pharma Intelligence Webinar, Designing the Deal: Layering the Groundwork for Successful Investment, Partnerships, and Acquisition, on June 29.

The world’s top pharmaceutical, medtech and clinical research organizations look to Pharma Intelligence for their authority, precision and forward-focused analysis. They offer webinars for clients that cover an array of topics and feature some of the best analysts and experts in the industry. Panel details are below.

Designing the Deal: Layering the Groundwork for Successful Investment, Partnerships, and Acquisition

Tuesday, June 29 |  1:00 – 2:00PM ET

A primary goal for most early-stage companies is to attract investment that ideally will lead to acquisition. In industries where IP constitutes the bulk of a company’s value, such as pharmaceuticals, the strength of a company’s patent portfolio can make or break its long-term prospects. Join Fish & Richardson’s Chad Shear, one of the world’s top life sciences patent prosecution attorneys, for a discussion of the steps pharmaceutical companies can take to lay the groundwork for successful deals.

Discussion topics will include:

  • What goes into a deal
  • How to optimize patent portfolios for investment, partnership, and acquisition
  • Due diligence for IP transactions
  • Availability of capital for early-stage companies

Moderator: Mandy Jackson, Managing Editor, Informa Pharma Intelligence

Speakers:

  • Chad Shear, Principal, Fish & Richardson
  • Dennis Purcell, Founder, Aisling Capital LLC
  • Kirsten Kester, VP of BD, Obsidian Therapeutics
  • Dr. Caroline Barelle, CEO, Elasmogen
  • Joshua Carle, MBA, VP of BD, Triumvira Immunologics

To learn more, or to attend, click here.